Zobrazeno 1 - 10
of 61
pro vyhledávání: ''
Autor:
Miguel Gil-Gil, José A. García-Sáenz, E Dalmau Portulas, Elena García-Martínez, Nuria Ribelles, A. Santaballa Bertran, E. Martínez de Dueñas, I Alvarez-Lopez, Susana Bezares
Publikováno v:
Dipòsit Digital de la UB
Universidad de Barcelona
Clinical & Translational Oncology
Universidad de Barcelona
Clinical & Translational Oncology
PurposeHormone receptor (HR)-positive, Human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (MBC) requires a therapeutic approach that takes into account multiple factors, with treatment being based on anti-estrogen hormo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b63a263cb82f360402dddafab187eefb
http://hdl.handle.net/2445/174389
http://hdl.handle.net/2445/174389
Autor:
Marcia Batista Salzgeber, T. T Benvenuti, João Carlos Sampaio Góes, Maria Lucia Hirata Katayama, Maria Aparecida Azevedo Koike Folgueira, Paulo Roberto Del Valle, Jane Haruko Lima Kaiano, Rosângela Portilho Costa Santos, Suzana Terumi Honda, Dirce Maria Carraro, Patricia Bortman Rozenchan, E. C. Lyra, Maria Mitzi Brentani, Cesar Torres, Helena Brentani
Publikováno v:
Tumour Biology
Our aim was to evaluate the interaction between breast cancer cells and nodal fibroblasts, by means of their gene expression profile. Fibroblast primary cultures were established from negative and positive lymph nodes from breast cancer patients and
Autor:
Feng Jin, Fan Yao, Yanan Sun, Ayao Guo, Chong Liu, Quanxiu Jin, Chuifeng Fan, Xiaoyun Mao, Bo Li, Shu Guan
Publikováno v:
Tumour Biology
CXCR4 and its ligand CXCL12 can promote the proliferation, survival, and invasion of cancer cells. They have been shown to play an important role in regulating metastasis of breast cancer to specific organs. High CXCR4 expression was also correlated
Publikováno v:
Molecular Imaging and Biology; Vol 13
Molecular Imaging and Biology
Molecular Imaging and Biology
Purpose The aim of this study is to use multicolor intravital imaging together with an inducible cell model to compare metastatic behavior of control and genetically modified breast cancer cell populations within the intact primary tumor of a mouse.
Autor:
Anupam Batra, C. Michael DiPersio, Anshu Aggarwal, David M. Jones, Rami N. Al-Rohil, Paul J. Feustel
Publikováno v:
BMC Cancer
Background Expression of integrin α3β1 is associated with tumor progression, metastasis, and poor prognosis in several cancers, including breast cancer. Moreover, preclinical studies have revealed important pro-tumorigenic and pro-metastatic functi
Publikováno v:
BMC Cancer
BMC CANCER(13)
BMC CANCER(13)
Background Heregulin (HRG; also known as neuregulin) is a ligand for ErbB3. One of its isotypes, HRG-β1, binds to ErbB3 and forms heterodimers with other ErbB family members, thereby enhancing the proliferation and tumorigenesis of breast cancer cel
Autor:
Nicole Lavender, Jiqing Sai, Ann Richmond, Philip Owens, Jinming Yang, C. Andrew Johnson, Gregory D. Ayers, Sheau-Chiann Chen
Publikováno v:
BMC Cancer
Background The role of the chemokine CCL2 in breast cancer is controversial. While CCL2 recruits and activates pro-tumor macrophages, it is also reported to enhance neutrophil-mediated anti-tumor activity. Moreover, loss of CCL2 in early development
Publikováno v:
Breast Cancer Research : BCR
Introduction New signaling pathways of the interleukin (IL) family, interferons (IFN) and interferon regulatory factors (IRF) have recently been found within tumor microenvironments and in metastatic sites. Some of these cytokines stimulate while oth
Publikováno v:
Breast Cancer Research : BCR
Introduction Transducin (β)-like 1 X-linked receptor 1(TBLR1) is an F-box-like and WD repeat-containing protein which functions as a switch in transcriptional activation, However, the clinical significance and biological role of TBLR1 in breast canc
Autor:
Adrienne Morey, Diana J. Hastrich, David Ingram, Peter C. Willsher, Arlene Chan, Belinda Brown
Publikováno v:
BMC Cancer, Vol 12, Iss 1, p 555 (2012)
BMC Cancer
BMC Cancer
Background Overall survival of HER2 positive metastatic breast cancer patients has been significantly improved with inclusion of trastuzumab to chemotherapy. Several studies have demonstrated discordant HER2 status in the primary and metastatic tumou